Navigation Links
LLS's Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
Date:9/20/2012

WHITE PLAINS, N.Y., Sept. 20, 2012 /PRNewswire/ -- Thanks to support funding from The Leukemia & Lymphoma Society (LLS), Onconova Therapeutics, Inc. has been advancing rigosertib, the lead compound under development for treating patients with high-risk myelodysplastic syndrome (MDS). 

In an announcement made this week, European commercial rights for rigosertib have been licensed to Baxter International providing significant resources to advance the program toward U.S. and European regulatory review and ultimately to MDS patients.  Rigosertib is designed to inhibit critical pathways to the growth and survival of cancer cells. 

"Advancing new therapies in areas of unmet medical need such as MDS is the bow of the ship for LLS," said LLS President and CEO John Walter. "The Baxter/Onconova agreement highlights a successful outcome for the LLS Therapy Acceleration Program (TAP)."

LLS and Onconova first announced their collaboration in June 2010. LLS has committed to providing up to $12.5 million in funding to support an ongoing multicenter, randomized, clinical trial of rigosertib versus best supportive care in adult patients with MDS who have relapsed or become resistant to azacitidine or decitabine. Onconova has announced that, to date, trial enrollment has successfully surpassed the half-way point and there are now 80 trial sites activated around the globe.  Onconova is continuing to accrue patients for the clinical trial.

This partnership marks the first phase 3, approval-track clinical trial that LLS is supporting through TAP, a bold initiative designed to bring promising therapies to patients suffering from blood cancers more quickly.  LLS is taking an active role in accelerating development of novel therapies for patients and&#
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
2. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
3. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
5. New gene therapy strategy boosts levels of deficient protein in Friedreichs ataxia
6. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
7. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
8. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
9. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
10. Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
11. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed ... that the United States Patent & Trademark Office (USPTO) issued ... September that is part of a standard essential family of ... , Application number: US 13/728,867 , Publication date: ... The listed inventors of the new patent, ...
(Date:9/20/2014)... HealthTronics, Inc. , a leading ... and services, has signed a distribution agreement through ... for its high precision laser technology. ... mobile, surgical technology—offering more choices for healthcare providers ... will make available Clinicon’s FDA-cleared SureLase™ CO2 Laser ...
(Date:9/19/2014)... than electricity, to move data would consume much ... growing concern as chips, transistor counts rise. , ... light emitters, modulators, and detectors emitters ... source for optical chips is molybdenum disulfide (MoS2), ... a single, atom-thick layer. Other experimental on-chip light ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
Breaking Biology Technology:Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2
... ... with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd ... transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 . , ... Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures ...
... CEL-SCI CORPORATION (NYSE AMEX: CVM ) announced ... covering its L.E.A.P.S.(TM) immune therapy drugs (vaccines) for the prevention/treatment ... or variants of these viruses. Some experts believe that ... have evolved and/or combined with other viruses to create a ...
... (NYSE AMEX: CVM ) , a ... entered into a definitive agreement with one institutional investor to ... of the Company,s common shares and 0.67 warrants to purchase ... $5.0 million, before deducting placement agent fees and estimated offering ...
Cached Biology Technology:PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group 2CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses 2CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses 3CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering 2CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering 3
(Date:9/19/2014)... Conn. , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... biometric authentication company focused on the growing m-commerce market, updates the ... world champion in the lightweight and light middleweight weight classes, ... Yesterday it was announced that Game of Thrones actor ... Married with Children star Katey Sagal have ...
(Date:9/18/2014)... circuit located deep in the primitive brainstem has revealed ... at Harvard School of Medicine and the University at ... only the second "sleep node" identified in the mammalian ... sufficient to produce deep sleep. , Published online in ... that fully half of all of the brain,s sleep-promoting ...
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2Microplastic pollution discovered in St. Lawrence River sediments 2
... Institute,s Bocas del Toro Research Station and Galeta ... temperature rise and a major coral bleaching event ... Oceanic and Atmospheric Administration, NOAA, issued an advisory ... the wider Caribbean region, there had been no ...
... At a press conference held in Brussels today, the ... European Parliament Osteoporosis Interest Group called on health care professionals ... prevent spinal fractures. The call to action was made at ... spine, leading up to World Osteoporosis Day on October 20, ...
... plants with red flowers or flowers with stripes along the ... Antirrhinum majus , at the John Innes Centre in the ... well as the plants in our gardens. The John Innes ... that can benefit agriculture and the environment. "Stripes following ...
Cached Biology News:Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean 2IOF campaign puts spotlight on vastly under-diagnosed and under-treated spinal fractures 2Landing lights for bumblebees 2
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
Biology Products: